Lunai Bioworks Inc.
$0.22-10.19%($-0.03)
TickerSpark Score
32/100
47
Valuation
40
Profitability
15
Growth
28
Health
30
Momentum
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LNAI research report →
52-Week Range2% of range
Low $0.15
Current $0.22
High $4.50
Companywww.renovarogroup.com
A company rebranding from Renovaro, focusing on AI-powered therapeutics and biodefense, with “Neurotoxicity Intelligence Technology” in development.
- CEO
- David H. Weinstein
- IPO
- 2025
- Employees
- 29
- HQ
- Los Angeles, CA, US
Price Chart
-90.14% · this period
Valuation
- Market Cap
- $4.00M
- P/E
- -0.04
- P/S
- 190.97
- P/B
- -0.59
- EV/EBITDA
- -0.23
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -360.71%
- Op Margin
- -46991.97%
- Net Margin
- -612568.11%
- ROE
- 892.52%
- ROIC
- 120.87%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-178,007,489 · -101.31%
- EPS
- $-10.78 · -18.46%
- Op Income
- $-18,546,573
- FCF YoY
- 28.68%
Performance & Tape
- 52W High
- $4.50
- 52W Low
- $0.15
- 50D MA
- $0.34
- 200D MA
- $1.03
- Beta
- 0.33
- Avg Volume
- 21.95M
Get TickerSpark's AI analysis on LNAI
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our LNAI Coverage
We haven't published any research on LNAI yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate LNAI Report →